Skip to content

Osteocrin and Vascular Complications

Osteocrin ,a Novel Predictive Bone-derived Humoral Factor,in Diabetes Mellitus, and Its Relation With Glycemic Control and Vascular Complications

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05719740
Acronym
Osteocrin
Enrollment
90
Registered
2023-02-09
Start date
2023-02-28
Completion date
2025-02-28
Last updated
2023-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Whether Osteocrin Levels Are Associated With Glycemic Control, Vascular Disorders in Diabetic Patients

Brief summary

In this study, we aimed to describe the role of bone-derived factor (osteocrin) in glucose metabolism, micro and macrovascular complications in diabetic patients. Thus, further investigations of the endocrine system through bone-derived hormones may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus.

Detailed description

Diabetes mellitus (DM) remained the most common metabolic disorder worldwide occupying the 8th leading cause of death.\[1\] Defining new predictive biomarkers in diabetes would provide a window of opportunity for preventive and/or therapeutic interventions to prevent or delay the onset of irreversible long-term micro and or macro vascular complications. Progressive micro vascular vaso-degeneration is the major factor in progression of diabetic complications and contribute greatly to the increased mortality and morbidity. \[2\] Where Hemodynamic-mediated vascular injury was considered as one mechanism in the pathogenesis of diabetic nephropathy. \[3\] Bone disorders have been drawing attention as a novel diabetic complication, and diabetes is associated with an increased risk of osteoporotic fracture \[4-6\]. Bone is considered as an endocrine organ that influences various organs and tissues via the secretion of multiple bone derived hormones \[7-8\]. These endocrinal functions are, for example, glucose homeostasis \[9\], appetite control \[10\], fat deposition \[11\], skeletal muscle adaptation \[12\], male fertility \[13\], and cognition \[14\]. Therefore, these bone-derived hormones can become useful biomarkers for predicting the incidence of diabetes and the progression of diabetic complications. Osteocrin (OSTN), a bone-derived humoral factor, is a small secreted peptide cloned from bone and muscle complementary DNA (cDNA) libraries \[15\]. Osteocrin (Ostn) is secreted protein produced by cells of the osteoblast lineage that shows a well conserved homology with members of the natriuretic peptide (NP) family with prohormone-like characteristics \[17\]. To date, the exact role of Ostn has not been elucidated. In this study, we aimed to describe the role of bone-derived factor (osteocrin) in glucose metabolism, micro and macrovascular complications in diabetic patients. Thus, further investigations of the endocrine system through bone-derived hormones may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus.

Interventions

DIAGNOSTIC_TESTosteocrin

laboratory routine test

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years

Inclusion criteria

\- Cases of the study will select randomly, based on inclusion criteria that included * Patients were diagnosed with diabetes mellitus according to American Diabetes Association * Age range 20-70 years * No apparent vascular abnormalities and Acute complications

Exclusion criteria

* Patients are excluded for participation in the study if * Patients had past history of cardiovascular events (heart failure or history of coronary artery disease), * infections, * aacute diabetic complications, * diabetic patients on regular hemodialysis . * acute illness, malignancy, or pregnancy.

Design outcomes

Primary

MeasureTime frame
to test and evaluate the role of bone-derived factor (osteocrin) in glucose metabolism,in diabetic patients with risk of micro and macrovascular complications .2 years

Secondary

MeasureTime frame
to identify bone-derived factor (osteocrin) may provide as new perspectives on the prediction, prevention, and treatment of diabetes mellitus1 year

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026